The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for ...

Faricimab should be readministered with caution in patients who develop mild intraocular inflammation with a previous dose of ...

WALTHAM, Mass. - Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.7 billion market cap biotech company showing impressive revenue growth of 162% over the last twelve months, today announced that the ...

Pharmaceuticals announced that the Therapeutic Goods Administration, TGA, has approved SYFOVRE or pegcetacoplan, for the ...

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month ...